NSC114792, a novel small molecule identified through structure-based computational database screening, selectively inhibits JAK3

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Kim, Byung Hak ^a   Jee, Jun Goo ^b   Yin, Chang Hong ^a   Sandoval, Claudio ^a   Jayabose, Somasundaram ^a   Kitamura, Daisuke ^c   Bach, Erika A ^d   Baeg, Gyeong Hun ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b TOKYO METROPOLITAN UNIVERSITY   (Japan)

^c TOKYO UNIVERSITY OF SCIENCE   (Japan)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

10,13 DIMETHYL 17 [2 (6 SULFANYLIDENE 3H PURIN 9 YL)ACETYL] 1,2,6,7,8,9,11,12,14,15,16,17 DODECAHYDROCYCLOPENTA[A]PHENANTHREN 3 ONE; INTERLEUKIN 2 RECEPTOR BETA; JANUS KINASE 3; JANUS KINASE 3 INHIBITOR; NSC 114792; STAT5 PROTEIN; UNCLASSIFIED DRUG; 10,13 DIMETHYL 17 (2 (6 SULFANYLIDENE 3H PURIN 9 YL)ACETYL) 1,2,6,7,8,9,11,12,14,15,16,17 DODECAHYDROCYCLOPENTA(A)PHENANTHREN 3 ONE; 10,13-DIMETHYL-17-(2-(6-SULFANYLIDENE-3H-PURIN-9-YL)ACETYL)-1,2,6,7,8,9,11,12,14,15,16,17-DODECAHYDROCYCLOPENTA(A)PHENANTHREN-3-ONE; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; DITERPENE; INTERLEUKIN 2; PROTEIN KINASE INHIBITOR; PURINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CATALYSIS; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG DETERMINATION; DRUG SCREENING; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN DOMAIN; CELL SURVIVAL; CHEMISTRY; COMPUTER INTERFACE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; MOLECULAR LIBRARY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALIA;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; DITERPENES; DOWN-REGULATION; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-2; JANUS KINASE 3; PROTEIN KINASE INHIBITORS; PURINES; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; STAT5 TRANSCRIPTION FACTOR; USER-COMPUTER INTERFACE;

EID: 77649145949     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-36     Document Type: Article

References (50)

1. Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev 2009, 228:273-287. 10.1111/j.1600-065X.2008.00754.x, 19290934.
2. Schindler C, Plumlee C. Interferons pen the JAK-STAT pathway. Semin Cell Dev Biol 2008, 19:311-318. 10.1016/j.semcdb.2008.08.010, 2741134, 18765289.
3. Rochman Y, Spolski R, Leonard WJ. New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol 2009, 9:480-490. 10.1038/nri2580, 2814538, 19543225.
4. Malaviya R, Uckun FM. Genetic and biochemical evidence for a critical role of Janus kinase (JAK)-3 in mast cell-mediated type I hypersensitivity reactions. Biochem Biophys Res Commun 1999, 257:807-813. 10.1006/bbrc.1999.0513, 10208864.
5. Papageorgiou AC, Wikman LE. Is JAK3 a new drug target for immunomodulation-based therapies?. Trends Pharmacol Sci 2004, 25:558-562. 10.1016/j.tips.2004.09.008, 15491777.
6. O'Shea JJ, Pesu M, Borie DC, Changelian PS. A new modality for immunosuppression: targeting the JAK/STAT pathway. Nat Rev Drug Discov 2004, 3:555-564. 10.1038/nrd1441, 15232577.
7. Walters DK, Mercher T, Gu TL, O'Hare T, Tyner JW, Loriaux M, Goss VL, Lee KA, Eide CA, Wong MJ, Stoffregen EP, McGreevey L, Nardone J, Moore SA, Crispino J, Boggon TJ, Heinrich MC, Deininger MW, Polakiewicz RD, Gilliland DG, Druker BJ. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell 2006, 10:65-75. 10.1016/j.ccr.2006.06.002, 16843266.
8. Kiyoi H, Yamaji S, Kojima S, Naoe T. JAK3 mutations occur in acute megakaryoblastic leukemia both in Down syndrome children and non-Down syndrome adults. Leukemia 2007, 21:574-576. 10.1038/sj.leu.2404527, 17252020.
9. Malinge S, Ragu C, Della-Valle V, Pisani D, Constantinescu SN, Perez C, Villeval JL, Reinhardt D, Landman-Parker J, Michaux L, Dastugue N, Baruchel A, Vainchenker W, Bourquin JP, Penard-Lacronique V, Bernard OA. Activating mutations in human acute megakaryoblastic leukemia. Blood 2008, 112:4220-4226. 10.1182/blood-2008-01-136366, 18755984.
10. Sato T, Toki T, Kanezaki R, Xu G, Terui K, Kanegane H, Miura M, Adachi S, Migita M, Morinaga S, Nakano T, Endo M, Kojima S, Kiyoi H, Mano H, Ito E. Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying Down syndrome. Br J Haematol 2008, 141:681-688. 10.1111/j.1365-2141.2008.07081.x, 18397343.
11. Mullighan CG, Zhang J, Harvey RC, Collins-Underwood JR, Schulman BA, Phillips LA, Tasian SK, Loh ML, Su X, Liu W, Devidas M, Atlas SR, Chen IM, Clifford RJ, Gerhard DS, Carroll WL, Reaman GH, Smith M, Downing JR, Hunger SP, Willman CL. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2009, 106:9414-9418. 10.1073/pnas.0811761106, 2695045, 19470474.
12. Cornejo MG, Kharas MG, Werneck MB, Le Bras S, Moore SA, Ball B, Beylot-Barry M, Rodig SJ, Aster JC, Lee BH, Cantor H, Merlio JP, Gilliland DG, Mercher T. Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models. Blood 2009, 113:2746-2754. 10.1182/blood-2008-06-164368, 2661862, 19139084.
13. Yared MA, Khoury JD, Medeiros LJ, Rassidakis GZ, Lai R. Activation status of the JAK/STAT3 pathway in mantle cell lymphoma. Arch Pathol Lab Med 2005, 129:990-996.
14. Gee K, Kozlowski M, Kryworuchko M, Diaz-Mitoma F, Kumar A. Differential effect of IL-4 and IL-13 on CD44 expression in the Burkitt's lymphoma B cell line BL30/B95-8 and in Epstein-Barr virus (EBV) transformed human B cells: loss of IL-13 receptors on Burkitt's lymphoma B cells. Cell Immunol 2001, 211:131-142. 10.1006/cimm.2001.1829, 11591117.
15. Lai R, Rassidakis GZ, Lin Q, Atwell C, Medeiros LJ, Amin HM. Jak3 activation is significantly associated with ALK expression in anaplastic large cell lymphoma. Hum Pathol 2005, 36:939-944. 10.1016/j.humpath.2005.07.011, 16153455.
16. Amin HM, Medeiros LJ, Ma Y, Fereyzaki M, Das P, Leventaki V, Rassidakis GZ, O'Conner SL, McDonell TJ, Lai R. Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma. Oncogene 2003, 22:5399-5407. 10.1038/sj.onc.1206849, 12934099.
17. Qui L, Lai R, Lin Q, Lau E, Thomazy DM, Calame D, Ford RJ, Kwak LW, Kirken RA, AMin HM. Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large cell lymphoma. Blood 2006, 108:2407-2415. 10.1182/blood-2006-04-020305, 1895569, 16763206.
18. Nakayama J, Yamamoto M, Hayashi K, Satoh H, Bundo K, Kubo M, Goitsuka R, Farrar MA, Kitamura D. BLNK suppresses pre-B-cell leukemogenesis through inhibition of JAK3. Blood 2009, 113:1483-1492. 10.1182/blood-2008-07-166355, 2644075, 19047679.
19. Jumaa H, Bossaller L, Portugal K, Storch B, Lotz M, Flemming A, Schrappe M, Postila V, Riikonen P, Pelkonen J, Niemeyer CM, Reth M. Deficiency of the adaptor SLP-65 in pre-B-cell acute lymphoblastic leukaemia. Nature 2003, 423:452-456. 10.1038/nature01608, 12761551.
20. Lin Q, Lai R, Chirieac LR, Li C, Thomazy VA, Grammatikakis I, Rassidakis GZ, Zhang W, Fujio Y, Kunisada K, Hamilton SR, Amin HM. Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. Am J Pathol 2005, 167:969-980. 1603671, 16192633.
21. Jeong EG, Kim MS, Nam HK, Min CK, Lee S, Chung YJ, Yoo NJ, Lee SH. Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers. Clin Cancer Res 2008, 14:3716-3721. 10.1158/1078-0432.CCR-07-4839, 18559588.
22. Abramovich C, Shulman LM, Ratovitski E, Harroch S, Tovey M, Eid P, Revel M. Differential tyrosine phosphorylation of the IFNAR chain of the type I interferon receptor and of an associated surface protein in response to IFN-alpha and IFN-beta. EMBO J 1994, 13:5871-5877. 395562, 7813427.
23. Choi YL, Kaneda R, Wada T, Fujiwara S, Soda M, Watanabe H, Kurashina K, Hatanaka H, Enomoto M, Takada S, Yamashita Y, Mano H. Identification of a constitutively active mutant of JAK3 by retroviral expression screening. Leuk Res 2007, 31:203-209. 10.1016/j.leukres.2006.05.006, 16790275.
24. Silvennoinen O, Witthuhn BA, Quelle FW, Cleveland JL, Yi T, Ihle JN. Structure of the murine Jak2 protein-tyrosine kinase and its role in interleukin 3 signal transduction. Proc Natl Acad Sci USA 1993, 90:8429-8433. 10.1073/pnas.90.18.8429, 47370, 8378315.
25. Chilton BS, Hewetson A. Prolactin and growth hormone signaling. Curr Top Dev Biol 2005, 68:1-23. 10.1016/S0070-2153(05)68001-5, 16124994.
26. Pesu M, Laurence A, Kishore N, Zwillich SH, Chan G, O'Shea JJ. Therapeutic targeting of Janus kinases. Immunol Rev 2008, 223:132-142. 10.1111/j.1600-065X.2008.00644.x, 2634846, 18613833.
27. Pesu M, Candotti F, Husa M, Hofmann SR, Notarangelo LD, O'Shea JJ. Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs. Immunol Rev 2005, 203:127-142. 10.1111/j.0105-2896.2005.00220.x, 15661026.
28. Kirken RA, Rui H, Malabarba MG, Farrar WL. Identification of interleukin-2 receptor-associated tyrosine kinase p116 as novel leukocyte-specific Janus kinase. J Biol Chem 1994, 269:19136-19141.
29. Cortes JR, Perez-G M, Rivas MD, Zamorano J. Kaempferol inhibits IL-4-induced STAT6 activation by specifically targeting JAK3. J Immunol 2007, 179:3881-3887.
30. Darnell JE. Validating Stat3 in cancer therapy. Nat Med 2005, 11:595-596. 10.1038/nm0605-595, 15937466.
31. Parsons SJ, Parsons JT. Src family kinases, key regulators of signal transduction. Oncogene 2004, 23:7906-7909. 10.1038/sj.onc.1208160, 15489908.
32. Bharti AC, Donato N, Aggarwal BB. Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 2003, 171:3863-3871.
33. Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 2003, 63:1270-1279.
34. Lipka DB, Hoffmann LS, Heidel F, Markova B, Blum MC, Breitenbuecher F, Kasper S, Kindler T, Levine RL, Huber C, Fischer T. LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells. Mol Cancer Ther 2008, 7:1176-1184. 10.1158/1535-7163.MCT-07-2215, 18483305.
35. Thoennissen NH, Iwanski GB, Doan NB, Okamoto R, Lin P, Abbassi S, Song JH, Yin D, Toh M, Xie WD, Said JW, Koeffler HP. Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells. Cancer Res 2009, 69:5876-5884. 10.1158/0008-5472.CAN-09-0536, 19605406.
36. Kim BH, Oh SR, Yin CH, Lee S, Kim EA, Kim MS, Sandoval C, Jayabose S, Bach EA, Lee HK, Baeg GH. MS-1020 is a novel small molecule that selectively inhibits JAK3 activity. Br J Haematol 2010, 148:132-143. 10.1111/j.1365-2141.2009.07925.x, 19793252.
37. Decker P, Isenberg D, Muller S. Inhibition of caspase-3-mediated poly(ADP-ribose) polymerase (PARP) apoptotic cleavage by human PARP autoantibodies and effect on cells undergoing apoptosis. J Biol Chem 2000, 275:9043-9046. 10.1074/jbc.275.12.9043, 10722754.
38. Nosaka T, van Deursen JM, Tripp RA, Thierfelder WE, Witthuhn BA, McMickle AP, Doherty PC, Grosveld GC, Ihle JN. Defective lymphoid development in mice lacking Jak3. Science 1995, 270:800-2. 10.1126/science.270.5237.800, 7481769.
39. Suzuki K, Nakajima H, Saito Y, Saito T, Leonard WJ, Iwamoto I. Janus kinase 3 (Jak3) is essential for common cytokine receptor gamma chain (gamma(c))-dependent signaling: comparative analysis of gamma(c), Jak3, and gamma(c) and Jak3 double-deficient mice. Int Immunol 2000, 12:123-132. 10.1093/intimm/12.2.123, 10653847.
40. Changelian PS, Flanagan ME, Ball DJ, Kent CR, Magnuson KS, Martin WH, Rizzuti BJ, Sawyer PS, Perry BD, Brissette WH, McCurdy SP, Kudlacz EM, Conklyn MJ, Elliott EA, Koslov ER, Fisher MB, Strelevitz TJ, Yoon K, Whipple DA, Sun J, Munchhof MJ, Doty JL, Casavant JM, Blumenkopf TA, Hines M, Brown MF, Lillie BM, Subramanyam C, Shang-Poa C, Milici AJ, Beckius GE, Moyer JD, Su C, Woodworth TG, Gaweco AS, Beals CR, Littman BH, Fisher DA, Smith JF, Zagouras P, Magna HA, Saltarelli MJ, Johnson KS, Nelms LF, Des Etages SG, Hayes LS, Kawabata TT, Finco-Kent D, Baker DL, Larson M, Si MS, Paniagua R, Higgins J, Holm B, Reitz B, Zhou YJ, Morris RE, O'Shea JJ, Borie DC. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 2003, 302:875-878. 10.1126/science.1087061, 14593182.
41. Stepkowski SM, Erwin-Cohen RA, Behbod F, Wang ME, Qu X, Tejpal N, Nagy ZS, Kahan BD, Kirken RA. Selective inhibitor of Janus tyrosine kinase 3, PNU15 prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin. Blood 6804, 99:680-689.
42. Deuse T, Velotta JB, Hoyt G, Govaert JA, Taylor V, Masuda E, Herlaar E, Park G, Carroll D, Pelletier MP, Robbins RC, Schrepfer S. Novel immunosuppression: R348, a JAK3- and Syk-inhibitor attenuates acute cardiac allograft rejection. Transplantation 2008, 85:885-892. 10.1097/TP.0b013e318166acc4, 18360272.
43. Pozzan A. Molecular descriptors and methods for ligand based virtual high throughput screening in drug discovery. Curr Pharm Des 2006, 12:2099-2110. 10.2174/138161206777585247, 16796558.
44. Goodsell DS, Morris GM, Olson AJ. Automated docking of flexible ligands: applications of AutoDock. J Mol Recognit 1996, 9:1-5. 10.1002/(SICI)1099-1352(199601)9:1<1::AID-JMR241>3.0.CO;2-6, 8723313.
45. Boggon TJ, Li Y, Manley PW, Eck MJ. Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. Blood 2005, 106:996-1002. 10.1182/blood-2005-02-0707, 1895152, 15831699.
46. Dolinsky TJ, Czodrowski P, Li H, Nielsen JE, Jensen JH, Klebe G, Baker NA. PDB2PQR: Expanding and upgrading automated preparation of biomolecular structures for molecular simulations. Nucleic Acids Res 2007, 35:W522-W525. 10.1093/nar/gkm276, 1933214, 17488841.
47. Case DA, Cheatham TE, Darden T, Gohlke H, Luo R, Merz KM, Onufriev A, Simmerling C, Wang B, Woods RJ. The Amber biomolecular simulation programs. J Comput Chem 2005, 26:1668-1688. 10.1002/jcc.20290, 1989667, 16200636.
48. Clevenger CV, Altmann SW, Prystowsky MB. Requirement of nuclear prolactin for interleukin-2--stimulated proliferation of T lymphocytes. Science 1991, 253:77-79. 10.1126/science.2063207, 2063207.
49. Zamorano J, Wang HY, Wang R, Shi Y, Longmore GD, Keegan AD. Regulation of cell growth by IL-2: role of STAT5 in protection from apoptosis but not in cell cycle progression. J Immunol 1998, 160:3502-3512.
50. Wu Z, Xue HH, Bernard J, Zeng R, Issakov D, Bollenbacher-Reilley J, Belyakov IM, Oh S, Berzofsky JA, Leonard WJ. The IL-15 receptor {alpha} chain cytoplasmic domain is critical for normal IL-15Ralpha function but is not required for trans-presentation. Blood 2008, 112:4411-4419. 10.1182/blood-2007-03-080697, 2597117, 18796634.